Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Arrakis Therapeutics on the deal. Arrakis Therapeutics announced its research collaboration agreement with Amgen (NASDAQ:AMGN), focused on the discovery and development of RNA degrader...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Eluminex Biosciences on the deal. Eluminex Biosciences (Suzhou) Limited (Eluminex) announced its acquisition of certain assets and the related global development and commercialization rights...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Global Blood Therapeutics on the deal. Global Blood Therapeutics, Inc. (Nasdaq: GBT) announced its offering of 1.875% Convertible Senior Notes due 2028. The...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
You must be a Standard 1 Year member to access this content.
Goodwin advised Enfusion on the deal, while Davis Polk advised the representatives of the several underwriters. Enfusion, Inc. completed its initial public offering of 21,562,500 shares...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Exscientia on the deal while Goodwin Procter represented Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Garuda Therapeutics on the deal. Garuda Therapeutics announced its launch and $72 million Series A financing led by Aisling Capital, Northpond Ventures, and OrbiMed,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised AbCellera on the deal. AbCellera (Nasdaq: ABCL) announced its acquisition of TetraGenetics. AbCellera is a technology company with a centralized operating system for next-generation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
You must be a Standard 1 Year member to access this content.
